Comparison of the course of multisystem inflammatory syndrome in children during different pandemic waves

Abstract The purpose of this study is to assess the rate, clinical picture, and management of multisystem inflammatory syndrome in children (MIS-C) during the different COVID-19 variants of concern (VOC) domination periods. This was a retrospective analysis of prospectively collected data. The incidence and clinical picture of MIS-C during the original/Alpha (group 1) and Delta/Omicron (Group 2) variant domination periods were compared. Among 108 eligible patients, 74 (68.5%) were hospitalized during the group 1 domination period, and 34 (31.5%) were hospitalized during the group 2 domination period. The median (Me) patient ages were 76 months (interquartile range [IQR] 35–130) and 73 months (IQR 45–118), and 61% and 65% of patients were male, respectively. There was no significant difference in the presence of positive SARS-CoV 2 antibody test results (IgM or IgG) between the groups (84 vs. 90%; p = 0.54).No differences between groups were observed in fever duration prior to admission (Me [IQR]: 5 days [3–6] vs. 5 days [4–6]; p = 0.26) or the presence of mucocutaneous (95 vs. 100%; p = 0.41), circulatory (70.3 vs. 61.8%; p = 0.86), neurological (6.8 vs. 2.9%; p = 0.662), or gastrointestinal symptoms (84 vs. 79%; p = 0.59). Respiratory symptoms were more common in group 2 (70 vs. 91%; p = 0.015). The need for intensive care unit admission was similar in both groups (16.2 vs. 17.6%, p = 1.0). No deaths occurred in the entire cohort. The studied children were characterized by high C-reactive protein and procalcitonin levels, concentrations of ferritin within normal limits, lymphopenia, moderate hypoalbuminemia, and high B-type natriuretic peptide/brain natriuretic peptide (NT-proBNP) concentrations; however, there were no differences between the groups. Intravenous immunoglobulins were administered as a first-line treatment for almost all patients. There was no significant difference in corticosteroid administration between the groups (87% vs. 74%; p = 0.11); however, the summary dose of methylprednisolone was higher in group 2 (Me [IQR]″ 12.6 mg/kg [10.5–17.8] vs. 16.4 mg/kg [13.3–19.5]; p = 0.03). The median length of stay was 11 days [IQR]: [9–14] and 10 days [8–12], respectively (p = 0.065). Conclusion: The clinical course of MIS-C is similar in subsequent pandemic waves; however, the incidence of MIS-C seems to be decreasing.What is Known:• The clinical picture of COVID-19 is evolving. Multisystem inflammatory syndrome in children (MIS-C) is a relatively new serious disease connected with SARS-CoV-2 infection, and in subsequent waves of the pandemic, new cases of the disease have been recorded.What is New:• The clinical picture of MIS-C is not specific, but the course is still severe.• The incidence of MIS-C during the different pandemic waves is decreasing and the diagnosis in the period of lower prevalance is challenging..

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:182
Enthalten in:	European journal of pediatrics - 182(2023), 4 vom: 31. Jan., Seite 1647-1656

Sprache:	Englisch

Beteiligte Personen:	Ptak, Katarzyna [VerfasserIn] Szymońska, Izabela [VerfasserIn] Olchawa-Czech, Anna [VerfasserIn] Kukla, Kornelia [VerfasserIn] Cisowska, Marta [VerfasserIn] Kwinta, Przemko [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	Clinical picture of MIS-C Incidence of MIS-C Multisystem inflammatory syndrome in children Severe acute respiratory syndrome-related coronavirus Variants of concern

Anmerkungen:	© The Author(s) 2023

doi:	10.1007/s00431-022-04790-4

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	SPR05238330X